“Liver–gut” axis: A target of traditional Chinese medicine for the treatment of non-alcoholic fatty liver disease

Ke, Guo; Xu, Sisheng; Zeng, Zhaofeng

doi:10.3389/fendo.2022.1050709

Cited by 8 publications

(3 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, the development and application of herbs and phytochemicals has become a research hotspot. Multiple studies have shown that the hepatoprotective activities of various herbs and phytochemicals were closely related to their regulatory effects on the gut-liver axis [70,71].…”

Section: Herbs and Phytochemicalsmentioning

confidence: 99%

Gut–Liver Axis as a Therapeutic Target for Drug-Induced Liver Injury

Tao,

Fan,

Wei

2024

CIMB

View full text Add to dashboard Cite

Drug-induced liver injury (DILI) is a liver disease that remains difficult to predict and diagnose, and the underlying mechanisms are yet to be fully clarified. The gut–liver axis refers to the reciprocal interactions between the gut and the liver, and its homeostasis plays a prominent role in maintaining liver health. It has been recently reported that patients and animals with DILI have a disrupted gut–liver axis, involving altered gut microbiota composition, increased intestinal permeability and lipopolysaccharide translocation, decreased short-chain fatty acids production, and impaired bile acid metabolism homeostasis. The present review will summarize the evidence from both clinical and preclinical studies about the role of the gut–liver axis in the pathogenesis of DILI. Moreover, we will focus attention on the potential therapeutic strategies for DILI based on improving gut–liver axis function, including herbs and phytochemicals, probiotics, fecal microbial transplantation, postbiotics, bile acids, and Farnesoid X receptor agonists.

show abstract

Section: Herbs and Phytochemicalsmentioning

confidence: 99%

Gut–Liver Axis as a Therapeutic Target for Drug-Induced Liver Injury

Tao,

Fan,

Wei

2024

CIMB

View full text Add to dashboard Cite

show abstract

“…Therefore, the traditional herbal compounds or formulas are usually targeted at harmonizing the function of “liver and spleen”. In preclinical studies, they are indicated to be beneficial in suppressing hepatic inflammation, regulating lipid profile and intestinal flora, and reducing LFC 78,79 . It is worth mentioning that the clinical trials on compound Chinese herbal medicines are all registered on the Chinese Clinical Trial Registry (http://www.chictr.org.cn), with no conclusive results yet (Table 3).…”

Section: Advances In Nafld/nash Treatment Regimens In Chinamentioning

confidence: 99%

Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review

Liu

Hong

2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim With industrialization and spread of the westernized lifestyle, the number of people affected by non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) is growing rapidly in China; this has become a major public health concern. To better understand the burden and characteristics of NAFLD/NASH in China, we aim to perform a narrative review of the literature published in this field. Materials and Methods We carried out a comprehensive electronic search of five English‐language and three Chinese‐language databases, to identify studies regarding NAFLD or NASH published from inception to November 30, 2022. Epidemiological studies of NAFLD/NASH in China were particularly noticed and summarized. We also searched the http://www.clinicaltrials.gov and http://www.chictr.org.cn websites for the registered trials on the treatment of the disease led by Chinese investigators or located in China. Results The increasing rate of NAFLD prevalence in China is strikingly high, reaching more than twice that in western countries. The prevalence of NAFLD is nearly 30% of the general Chinese population, making it the leading cause of chronic liver diseases. The prevalence of NAFLD/NASH varies between provinces/regions, age groups, sexes, and individuals with different metabolic profiles. NAFLD co‐exists in many Chinese patients with chronic hepatitis B. Since 2020, more Chinese studies have used the term metabolic‐associated fatty liver disease (MAFLD), emphasizing the underlying metabolic disorders that occur concurrently with this disease. Several clinical trials involving lifestyle interventions, antidiabetic drugs, or traditional Chinese medicines, registered by Chinese investigators, have been completed or are ongoing. Moreover, several innovative targeted therapies developed in China are revolutionizing the treatment of NAFLD/NASH. Conclusions NAFLD has cast a heavy burden on the Chinese healthcare system. Chinese scholars are making efforts to achieve the optimal management of this disease.

show abstract

“…The emerging field of intestinal microecology has shed light on the potential of regulating the gut-liver axis as a treatment for NAFLD. 4 Numerous recent studies have identified a link between gut microbiome changes and NAFLD’s pathogenesis. Certain bacterial strains, such as Lactobacillus , Bifidobacterium , Akkermansia muciniphila , and Bacteroides uniformis , have been found to have protective effects against NAFLD in animal models.…”

Section: Introductionmentioning

confidence: 99%

Bacteroides thetaiotaomicron ameliorates mouse hepatic steatosis through regulating gut microbial composition, gut-liver folate and unsaturated fatty acids metabolism

Li,

Wang,

Tang

et al. 2024

Gut Microbes

View full text Add to dashboard Cite

Gut microbiota plays an essential role in the progression of nonalcoholic fatty liver disease (NAFLD), making the gut-liver axis a potential therapeutic strategy. Bacteroides genus, the enriched gut symbionts, has shown promise in treating fatty liver. However, further investigation is needed to identify specific beneficial Bacteroides strains for metabolic disorders in NAFLD and elucidate their underlying mechanisms. In this study, we observed a positive correlation between the abundance of Bacteroides thetaiotaomicron ( B. theta ) and the alleviation of metabolic syndrome in the early and end stages of NAFLD. Administration of B. theta to HFD-fed mice for 12 weeks reduced body weight and fat accumulation, decreased hyperlipidemia and insulin resistance, and prevented hepatic steatohepatitis and liver injury. Notably, B. theta did not affect these indicators in low-fat diet (LFD)-fed mice and exhibited good safety. Mechanistically, B. theta regulated gut microbial composition, characterized by a decreased Firmicutes/Bacteroidetes ratio in HFD-Fed mice. It also increased gut-liver folate levels and hepatic metabolites, alleviating metabolic dysfunction. Additionally, treatment with B. theta increased the proportion of polyunsaturated fatty acid in the mouse liver, offering a widely reported benefit for NAFLD improvement. In conclusion, this study provides evidence that B. theta ameliorates NAFLD by regulating gut microbial composition, enhancing gut-liver folate and unsaturated fatty acid metabolism, highlighting the therapeutic role of B. theta as a potential probiotic for NAFLD.

show abstract

“Liver–gut” axis: A target of traditional Chinese medicine for the treatment of non-alcoholic fatty liver disease

Cited by 8 publications

References 65 publications

Gut–Liver Axis as a Therapeutic Target for Drug-Induced Liver Injury

Gut–Liver Axis as a Therapeutic Target for Drug-Induced Liver Injury

Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review

Bacteroides thetaiotaomicron ameliorates mouse hepatic steatosis through regulating gut microbial composition, gut-liver folate and unsaturated fatty acids metabolism

Contact Info

Product

Resources

About